Watkins Tim 4
4 · Contineum Therapeutics, Inc. · Filed Jul 1, 2026
Research Summary
AI-generated summary of this filing
Contineum Therapeutics (CTNM) CMO Tim Watkins Sells Shares After Exercising Options
What Happened
Tim Watkins, Chief Medical Officer & Head of Development at Contineum Therapeutics (CTNM), exercised options and sold the underlying shares on June 30, 2026. He exercised 10,833 option shares at an exercise price of $4.50 (cost $48,749) and sold those 10,833 shares in the open market for a weighted average price of $16.02, generating proceeds of about $173,590. The filing also shows a related derivative conversion/disposition line for 10,833 shares at $0.00 (see filing for detail).
Key Details
- Transaction date: June 30, 2026; Form 4 filed July 1, 2026 (timely filing).
- Exercise: 10,833 shares at $4.50 each = $48,749 (transaction code M).
- Sale: 10,833 shares sold at weighted avg $16.02 = ~$173,590 (transaction code S); sale prices ranged $16.00–$16.15 per footnote.
- Additional derivative line: 10,833 shares reported as disposed at $0.00 (transaction code M); see filing for specifics.
- Plan/controls: Transactions were effected under a 10b5-1 trading plan adopted Sept 23, 2025.
- Vesting/other: Footnotes note vesting schedule for option shares (half vested Oct 28, 2025; remainder vests monthly) and 8,961 ESPP shares exempt under 16a-3/16b-3 rules.
- Shares owned after transaction: Not specified in the provided excerpt of the filing.
Context
Because the option exercise and sale occurred the same day, this looks like a cashless-type exercise where shares were exercised and immediately sold. The sale was executed under a pre-established 10b5-1 plan, which is a trading arrangement that schedules transactions in advance and is common for executive sales. The filing is factual and does not indicate the insider’s intent.
Insider Transaction Report
- Exercise/Conversion
Class A Common Stock
[F1]2026-06-30$4.50/sh+10,833$48,749→ 19,794 total - Sale
Class A Common Stock
[F1][F2][F3]2026-06-30$16.02/sh−10,833$173,590→ 8,961 total - Exercise/Conversion
Stock Option (right to buy)
[F1][F4]2026-06-30−10,833→ 238,334 totalExercise: $4.50Exp: 2035-04-27→ Class A Common Stock (10,833 underlying)
Footnotes (4)
- [F1]These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- [F3]Includes 8,961 shares of the Issuer's Class A Common Stock acquired by the Reporting Person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c).
- [F4]One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service.